Micron-sized and submicron-sized aerosol deposition in a new  preclinical model by unknown
RESEARCH Open Access
Micron-sized and submicron-sized aerosol
deposition in a new ex vivo preclinical
model
Sophie Perinel1,2,3, Lara Leclerc1,2,4*, Nathalie Prévôt1,2,3, Agathe Deville2,3, Michèle Cottier1,2,3, Marc Durand1,5,
Jean-Michel Vergnon1,2,3 and Jérémie Pourchez1,2,4
Abstract
Background: The knowledge of where particles deposit in the respiratory tract is crucial for understanding the
health effects associated with inhaled drug particles.
Method: An ex vivo study was conducted to assess regional deposition patterns (thoracic vs. extrathoracic) of
radioactive polydisperse aerosols with different size ranges [0.15 μm–0.5 μm], [0.25 μm–1 μm] and [1 μm–9 μm].
SPECT/CT analyses were performed complementary in order to assess more precisely the regional deposition of
aerosols within the pulmonary tract.
Experiments were set using an original respiratory tract model composed of a human plastinated head connected
to an ex vivo porcine pulmonary tract. The model was ventilated by passive expansion, simulating pleural depressions.
Aerosol was administered during nasal breathing.
Results: Planar scintigraphies allowed to calculate the deposited aerosol fractions for particles in the three size ranges
from sub-micron to micron The deposited fractions obtained, for thoracic vs. extra-thoracic regions respectively, were
89 ± 4 % vs. 11 ± 4 % for [0.15 μm–0.5 μm], 78 ± 5 % vs. 22 ± 5 % for [0.25 μm–1 μm] and 35 ± 11 % vs.65 ± 11 % for
[1 μm–9 μm].
Conclusion: Results obtained with this new ex vivo respiratory tract model are in good agreement with the in vivo
data obtained in studies with baboons and humans.
Keywords: Aerosoltherapy, Aerosol deposition, SPECT/CT imaging
Background
The effectiveness of aerosol drug delivery mainly de-
pends on the amount of active agent penetrating the re-
spiratory tract as well as on its regional distribution.
This information is crucial for predicting the beneficial
health effects associated with inhaled drug particles.
Many inhalation studies were mainly focused on the as-
sessment of the total deposited fraction (often calculated
by comparison between inhaled and exhaled fractions)
or used computational approaches, for instance, the re-
cent Euler-Lagrangian approach of Kannan et al. [1]. In
their study, high fidelity computational simulations were
performed over several breathing cycles to get the re-
gional deposition for different particle sizes and an algo-
rithm was devised to account for the re-entry of
particles during the exhalation phase. However some at-
tempts were devoted to the quantification of regional
particle deposition [2–4]. Nevertheless, in vivo experi-
mental studies on the regional deposition of submicron-
sized particles are still quite scarce.
In vivo experiments using radioactive aerosols are
widely considered as the gold standard in order to assess
the regional deposition of airborne particles. However,
obtaining rapidly an extensive experimental dataset in
human using radioactive aerosols is difficult and ques-
tionable due to ethical restrictions. Thus, in vivo labora-
tory animal studies are an attractive alternative. On the
one hand, rodents, like rats or mice, that are most often
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used for such inhalation experiments [5, 6] are disparate
from the human airways by size, bronchial divisions,
anatomy of upper airways and respiratory physiology [7].
As an example, the respiratory rate at rest is around 80
breaths per minute for rats compared to 15 breaths per
minute for humans. In these conditions, researchers
have to be careful when translating results from in vivo
experiments on rodents to humans even if they are help-
ful to understand deposition mechanisms. On the other
hand, radioactive aerosol deposition studies have also
been performed using pigs or non-human primates be-
cause of their anatomical proximity with human airways
[8–11]. However, the main limits of these in vivo labora-
tory animal studies are ethical restrictions as well as cost
and technical constraints (e.g., anesthesia that is often
necessary to perform inhalation experiments, specialized
laboratories, etc.). Furthermore, the breathing pattern,
known to be an important factor for inhalation efficiency
(Inspired/Expired ratio, frequency, obstruction etc.), is
difficult to control in spontaneously breathing pigs or
non-human primates.
As an alternative to in vivo inhalation experiments on
humans and laboratory animals, ex vivo anatomical
models such as cadaver heads [12] or in vitro nasal casts
using prototyping techniques [13, 14] have been devel-
oped. These models are very accurate to assess aerosol
drug deposition in nasal cavities such as maxillary si-
nuses [15–19]. Nasal casts are morphologically close to
the human anatomy and easier to handle compared to
in vivo preclinical models. However, even if these rep-
licas are useful for inhalation studies in nasal cavities,
very few in vitro or ex vivo anatomical models mimic a
human-like respiratory tract including both extrathor-
acic [ET] and thoracic [TH] regions and a physiological
breathing pattern.
This article focuses on an original solution to bridge
the existing gap on anatomical respiratory models to as-
sess regional aerosol deposition. This study used an ex
vivo human-like respiratory tract model [20]. This
chimeric model is composed of a human plastinated
head linked to an ex vivo porcine pulmonary tract venti-
lated artificially by inflation with a negative pressure in-
side a sealed enclosure (passive expiration). This cheaper
and original approach without ethical restriction allows
assessing regional aerosol deposition in both extrathor-
acic and pulmonary regions.
The clinical context of this study is the topical nasal
drug delivery. When developing a drug product for nasal
delivery, the aerodynamic features of the formulation
have to ensure that drug particles are retained in the
nasal cavity and not inhaled into the lung. For example,
airborne drug delivery to the maxillary sinuses requires
variable pressure application (known as ‘pulsating air-
flow’ aerosols) [15–19, 21] but also small droplets (with
a MMAD lower than 5 μm) [22]. The main challenge
consists of delivering a high concentration of medication
into the maxillary sinus cavities while at the same time
preventing unwanted lung deposition observed with
small particle delivery systems in order to minimize side
effects. Therefore, the optimal droplet size for nasal ad-
ministration should be based, among other things, on an
accurate assessment of aerosol regional deposition in
both extra thoracic and pulmonary regions.
The experiments were conducted using radioactive
polydisperse aerosols in the [0.15 μm–0.5 μm],
[0.25 μm–1 μm] and [1 μm–9 μm] ranges. We used ex-
clusively a nasal administration of aerosol. We measured
regional deposition in the TH region versus the ET re-
gion using planar scintigraphies and single-photon emis-
sion computed tomography (SPECT) [11, 13]. The
secondary objective was to evaluate the reliability of this
ex vivo model for aerosol deposition by comparison with
known in vivo data in humans and baboons using the




Experiments were performed using an ex vivo respira-
tory tract model. This model is composed of a human
plastinated head linked to an ex vivo porcine pulmonary
tract ventilating artificially by passive expansion with de-
pressions. The laryngeal part is made of plastic tubes
with a one-way valve simulating the resistance of vocal
folds as inhalation is ongoing. An other one-way valve
allows the path for exhalation as previously described
[13]. The human plastinated head was anatomically, geo-
metrically and aerodynamically characterized [12].
Physiological parameters obtained were consistent with
the widely accepted human physiology [20]. Experimen-
tal conditions used were biomimetic with an original
breathing technological process simulating the intra-
pleural depressions. Indeed, the chimeric model respired
artificially by inflation with a negative pressure (passive
expiration) applied inside an instrumented sealed enclos-
ure developed specifically for this model [20]. The inhal-
ation is due to the depression inside the instrumented
sealed enclosure and the exhalation is passive by the re-
turn to atmospheric pressure by a pause of the depres-
sion generator. Moreover the duration of inhalation and
exhalation in the respiratory cycle are chosen with
shorter time duration for inhalation. In order to fit the
human physiology, a ratio of 1.3 s for inhalation and
2.6 s for exhalation has been chosen, leading to a re-
spiratory cycle of 4 s and consequently a respiratory rate
of 15/min. In these conditions, the breathing parameters
selected correspond to adult male physiology at rest:
breathing rate of 15 breaths per minute, calculated mean
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tidal volume [VT] of 824 mL (SD 207 mL), inspiratory-
to-expiratory time [I/E] ratio of 1/2, ET deadspace of
21 mL, tracheal internal diameter of 1.7 cm [23–25].
The chimeric model satisfied the major functional and
anatomical features necessary to study deposition of air-
borne particles [20]. The experimental setup for inhal-
ation experiments is described in Fig. 1. The position of
the exhalation filter is due to a particularity of the plasti-
nated head (closed mouth) so obtained results corres-
pond to an approximation of the exhaled fraction.
Aerosol generation and characterization
Medical jet nebulizers are used to generate radioactive
polydisperse aerosols from sub-micron to micron-sized
particles. The nebulizing systems chosen are an Atomisor
NL11 (DTF Medical, France), a modified Sidestream
(Philips Respironics, Ref 12NEB400, England), and a
Nanoneb (DTF Medical, France) operating at a flow rate
of 6 L/min. The same experimental conditions concerning
the generation of radioactive polydisperse aerosols were
used as in previous in vivo studies performed in humans
and baboons [11, 17].
Briefly, the nebulizer (Atomisor NL11, Sidestream or
Nanoneb) was associated with a same AOHBOX air
source compressor (Diffusion Technique Française, DTF
Medical, Saint-Etienne, France). The nebulizers were
connected to a nasal plug (C28 medium size, DTF
Medical, France) usually employed in clinical practice.
This plug ensures the interface connection between the
nebulizer and plastinated head nostrils. For each experi-
ment, nebulizers (n = 4) were loaded with 4 mL of a so-
lution containing 740 MBq of 99mTc-DTPA (TechneScan
DTPA, Mallinckrodt Medical, Petten, the Netherlands)
and the duration of nebulization was standardized to
10 min as previously described [13, 18, 19, 21].
Radioactive aerosols are well characterized in terms of
particle sizing and aerosol output according to protocols
developed in previous works [11, 13]. Succinctly, particle
size distributions of radioactive aerosols were determined
using a gamma camera (Ecam; Siemens, Germany) coupled
to a specific electrical low-pressure impactor (ELPI; Dekati,
Finland) using the DLPI mode (without the corona charger
of ELPI instrument). The DLPI mode allows avoiding pos-
sible biases induced by the corona charger (particle size se-
lection phenomena and possible particle losses). The
particles were impacted depending on their inertia-related
aerodynamic diameter on one of the 12 size fraction stages
of the impactor in the 30 nm - 10 μm range. Finally the
radioactivity from aerosol particles deposited in each size-
specific stage was quantified by scintigraphic imaging. It
allowed direct tracing of the activity distribution as a func-
tion of aerosol aerodynamic size. Thus, the knowledge of
the radioactivity dose deposited on each impactor stage
permitted the calculation of:
– the activity median aerodynamic diameter (AMAD)
with geometric standard deviation (GSD),
– the total dose of radioactivity delivered by the
nebulizer (i.e. the nebulizer emitted fraction),
– the fine particle (FP) fraction (including all particles
with an aerodynamic diameter <2.5 μm) and the
ultrafine particle (UFP) fraction (including all
particles with an aerodynamic diameter <0.1 μm),
– and the [d16–d84] particle size range (where d16
and d84 are respectively the particle diameters at
the 16 and 84 % size cut-offs of the cumulative
distribution).
Aerosol regional deposition
2D gamma-imaging acquisition and image analysis procedure
The planar scintigraphic images (matrix 256*256) were
recorded with a variable angle dual detector SPECT/ CT
(SYMBIA T2; Siemens, Knoxville, TN) equipped with a
low-energy, high-resolution collimator (FWHM 8.3 mm
at 10 cm); tested weekly for uniformity (UFOV 533 mm ×
387 mm, CFOV 400 mm × 290 mm).
Before conducting the inhalation experiments, the initial
radioactive dose filled in the nebulizer was quantified
(scintigraphic images, 60-sec anterior/posterior, were ac-
quired corresponding to the full and empty syringe). Once
Fig. 1 a Schematic of the experimental setup for nebulization using the human-like ex vivo preclinical model. 1) plastinated human head, 2) one-way
valves, 3) plastic tubes, 4) expiratory filter, 5) porcine pulmonary tract, 6) plastic sealed enclosure, 7) respiratory pump, 8) nasal plug, 9) jet nebulizer,
10) compressor. b Photograph of the setup before the start of the aerosol experiments
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the inhalation experiments were performed, 180-sec an-
terior/posterior images of the experimental setup were ac-
quired for each element: empty nebulizer, expiratory filter,
human plastinated head and lungs as shown on Fig. 2.
A region of interest (ROI) was delimited on the images
with a correction of the background using the mean of
three external ROIs. Calculations took into account the
background radiation, physical decay of radioactivity and
tissue attenuation correction factors.
Results were expressed in terms of the activity
loaded into the nebulizer and the ratio between TH
and ET regions corresponding respectively to the
lungs with the tracheobronchial tree and to the head
with the artificial larynx.
3D gamma-imaging acquisition and image analysis
procedure
After acquiring 2D images with the same gamma camera
(SYMBIA T2; Siemens, Knoxville, TN), SPECT and CT
acquisitions were performed immediately (without
moving the lungs) which have a 2-slice spiral CT for a
more rapid and accurate attenuation correction and ana-
tomical mapping. A 3D SPECT acquisition of the lungs
was performed with 64 (2 × 32) projection images, each
of 30s. Finally, a CT was performed with the following
parameters: 130 kV, 90 mAs, 1.25 mm slice thickness,
0.9 mm increment, 1.6 mm pitch, and rotation time of
1.5 s. A multimodality computer platform (Symbia net;
Siemens) was used for image reviews and manipulations.
Fig. 2 Definition of the 2D imaging anatomical regions of interest (ROIs). Illustrative images of the planar scintigraphies obtained after each
experiment. ROIs are delimited in red and the three green squares on each image correspond to the background evaluations
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Both the transmission and emission scans were recon-
structed using 3D OSEM by default (8 subsets, 5 itera-
tions), with pre-reconstruction smoothing using a 3D
Butterworth filter (cutoff: 0.45 cycles/cm; order 5), a
128 × 128 image matrix, a 1.23 zoom, and a pixel size of
3.9 mm. SPECT images were reconstructed using scatter
correction (scatter energy window) and CT attenuation
correction. CT and SPECT images were matched and
fused into trans-axial images. A multimodality computer
platform (Symbia net; Siemens) was used for image re-
view and manipulation. Different 3D ROIs were drawn
on the CT images with the software to delimit peripheral
areas from proximal tracheobronchial areas of the lungs.
Results
Particle size distribution
As summarized in Table 1, the nebulizing systems led to
different AMAD from sub-micron to micron sized parti-
cles: 2.8 μm (GSD of 3.2) for the Atomisor NL11, 550 nm
(GSD of 2.1) for the Sidestream, and 230 nm (GSD of 1.6)
for the Nanoneb. The geometric standard deviation clearly
showed that the particle size distributions are broad and
quite far from a monodisperse distribution. Thus the aero-
sol distribution can be characterized by the means of the
[d16–d84] particle size range: [1 μm–9 μm] for Atomisor
NL11, [0.25 μm–1 μm] for the modified Sidestream and
[0.15 μm–0.5 μm] for the Nanoneb.
Regional aerosol deposition by 2D gamma-imaging
The ROIs determined by 2D imaging after planar scin-
tigraphies allowed to quantify the ET and TH deposited
fractions (Table 2) but also an approximation of the ex-
haled fraction (Fig. 3) after the nasal administration of
the polydisperse aerosol.
Besides, the exhaled fraction decreased as the size of
aerosol increased. More precisely, for the [0.15 μm–0.5 μm]
aerosol particles, we noticed a very significant exhaled frac-
tion (68 ± 12 %, expressed as a percentage of the emitted
aerosol fraction by the nebulizer). In contrast, the exhaled
fraction for the [0.25 μm–1 μm] and the [1 μm–9 μm]
aerosol particles was quite similar (respectively 34 ± 11 %
and 27 ± 9 %).
ET deposited fractions obtained for the three types
of polydisperse aerosols were 11 ± 4 % for the
[0.15 μm–0.5 μm] size range, 22 ± 5 % for [0.25 μm–1 μm]
range and 65 ± 11 % for [1 μm–9 μm] range. In the same
way, TH deposited fractions were 89 ± 4 % for the
[0.15 μm–0.5 μm] size range, 78 ± 5 % for [0.25 μm–1 μm]
aerosol and 35 ± 11 % for [1 μm–9 μm] aerosol. These data
were compared to known in vivo data obtained in previous
studies with baboons and humans (Table 2) using similar
experimental conditions [11, 17].
Pulmonary deposition assessed by SPECT/CT
The 3D anatomical ROIs determined by CT scans with
radioactivity counted by SPECT are shown in Fig. 4.
With this methodology, the ROI outlines allowed the de-
limitation of the proximal and peripheral regions of the
lungs. The proximal region corresponds to the trachea
and the two principal bronchi. Representative SPECT-
CT images of regional lung deposition obtained for the
different polydisperse aerosols are shown in Fig. 4a.
Interestingly, there were no significant differences
among the three types of polydisperse radioactive aero-
sols [26]. Indeed, a large deposition of aerosols was
clearly visible in the peripheral lung region whereas a
low amount of radiolabeled airborne particles was de-
posited in the proximal tracheobronchial region (less
than 5 % of the total aerosol deposition). The percent-
ages of aerosol deposited in the lung (see ET fraction in
Table 2) were normalized to 100 % to compare the prox-
imal (central) versus peripheral regions of the lungs and
are illustrated in Fig. 4b. The thoracic deposition per-
centage varies significantly in the model depending on
the AMAD but whatever the thoracic deposition
amount, this deposit is still peripheral.
Discussion
In this study, the use of the chimeric model appeared
useful in performing regional aerosol deposition cartog-
raphies for nasally administered aerosols. Moreover, the
ET and TH deposited fractions for particles in the
[1 μm–9 μm] and the [0.15 μm–0.5 μm] range were in
acceptable agreement between inhalation experiments
on baboons, healthy human volunteers and the chimeric
model (i.e. respectively 72 ± 17 %, 72 ± 14 %, 65 ± 11 %
for ET deposited fraction for the [1 μm–9 μm] size range)
with non significant statistical differences (p = 0.4799). By
contrast, significant differences (p < 0.0001) were noticed
for the [0.25 μm–1 μm] aerosol (i.e. 22 ± 5 % in the
chimeric model versus 49 ± 8 % in baboons for the ET de-
posited fraction).
Anatomically, the respiratory tracts of pigs are very
similar to those of humans, with the same 23
Table 1 Features of the inhaled aerosols to assess the impact of particle size on the regional distribution
Nebulizers AMAD GSD Aerosol output Particles <1 μm Particles <0,5 μm [d16–d84]
NL11 2.80 μm 3.2 44.5 ± 1.5 % 13.6 ± 1.6 % 4.7 ± 0.6 % [1 μm–9 μm]
Sidestream 550 nm 2.1 9.3 ± 3 % 89.2 ± 2 % 47.9 ± 4.4 % [0.25 μm–1 μm]
Nanoneb 230 nm 1.6 4.2 ± 1 % 97.5 ± 0.5 % 86.6 ± 1.8 % [0.15 μm–0.5 μm]
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branching divisions except for position of the tracheal
bronchus, making pigs very good animal models of the
human respiratory tract for decades [27]. Because its
half-life after death is a few hours, surfactant is miss-
ing in the ex vivo porcine lung. This had to be taken
into account in our experimental conditions. The sim-
ulated intra-pleural depressions necessary to inflate
the lungs in the sealed enclosure were adjusted to
compensate the absence of surfactant. As a result, the
model requires twice the values of depression usually
obtained for intrapleural depression during human
breathing, which is consistent with the biomechanical
role of the surfactant (approximately 50 % of the com-
pliance) [28]. It has to be noted that the absence of
blood circulation in this model impacts the compli-
ance too.
Besides, limitations of inhalation experiments using
the chimeric model have to be underlined which could
explain differences observed for airborne particles in the
[0.25 μm–1 μm] range.
On the one hand, the flap valve installed to simulate
the vocal folds may filter larger particles much less or
more effectively than real vocal folds depending on the
occluded area and the flexibility. Nevertheless, the valve’s
size and resistivity were carefully selected and this sys-
tem has already been described and used in previous
studies [13, 18]. Moreover previous studies using the
proposed model were for gas ventilation (radioactive
krypton) experiments without aerosols (i.e. particles or
droplets suspended in the air). These points have to be
taken into account for the extrathoracic/thoracic results
reported in Table 2.
On the other hand, in the chimeric model, the inhal-
ation mode and postural conditions vary from the com-
pared studies (in vivo inhalation experiments with
baboon and healthy human volunteer):
Table 2 Deposited fractions in extrathoracic (ET) and thoracic (TH) regions for the different types of polydisperse radioactive
aerosols. Results are expressed in ratio (%) of the total deposited fraction (mean ± SD). Comparison of experimental results obtained
with the chimeric model to baboon and human in vivo experimentations realized in previous studies [11, 17]
[0.15 μm–0.5 μm] [0.25 μm–1 μm] [1 μm–9 μm]
Chimeric model (Supine position) ET 11 ± 4 % 22 ± 5 % 65 ± 11 %
TH 89 ± 4 % 78 ± 5 % 35 ± 11 %
Human (Erect position) ET NC NC 72 ± 14 %
TH NC NC 28 ± 12 %
Baboon (Erect position) ET 16 ± 4 % 49 ± 8 % 72 ± 17 %
TH 84 ± 4 % 51 ± 8 % 28 ± 17 %
Fig. 3 Respective percentages of exhaled fractions obtained for each [d16–d84] size range: [0.15 μm–0.5 μm], [0.25 μm–1 μm] and [1 μm–9 μm].
Results are expressed in ratio (%) of the nebulizer emitted fraction (mean ± SD, **p < 0,01)
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– supine position with a nasal administration of the
aerosol was used during the experiments with the
chimeric model.
– erect position with a nasal administration of the
aerosol for the in vivo human experiments.
– erect position with an oro/nasal administration for
the in vivo baboon experiments.
For a given airborne particle size range and thus a spe-
cific deposition mechanism, this variation of inhalation
mode and postural condition can play an important role
and have a direct impact on comparisons between ba-
boon, human and the chimeric model. Indeed, airborne
particles can deposit by different ways in the respiratory
tract, and it is possible to correlate the aerodynamic di-
ameters to the deposition mechanisms in the respiratory
airways. Inertial impaction, gravitational sedimentation,
and turbulence-driven diffusion mainly govern the de-
position of aerosol particles. Each deposition mechanism
is directly related to aerodynamic particle size, airway
geometry and particle velocity [29–32]. For example, the
respiratory deposition of particles in the [1 μm–9 μm],
[0.15 μm–0.5 μm] and [0.25 μm–1 μm] size ranges are
governed mainly by impaction, turbulence-driven diffu-
sion and sedimentation mechanisms, respectively.
Turbulence-driven diffusion mechanism is by random
Brownian diffusion mainly in the pulmonary region.
Some researchers have recently differentiated a turbulent
diffusion mechanism as an addition to their impaction
models in the upper airways [33].
It seems interesting to notice that the correlation of in
vivo experiments performed in baboon and human com-
pared to the ex vivo model is in good agreement for all
airborne particle sizes, except those that have a mechan-
ism of deposition by sedimentation mainly due to by
gravity, i.e. the [0.25 μm–1 μm] range. Concerning the
[1 μm–9 μm] aerosols, the deposition pattern observed
in human, baboon and ex vivo model is very similar
(around 70 % of deposition in the ENT region, p =
0,4799, no significant difference). These results confirm
that there is no impact of the inhalation mode and the
postural conditions when the deposition of aerosols is
mainly governed by impaction. Similarly for the
[0.15 μm–0.5 μm] aerosols, deposition is comparable
between baboon and the ex vivo model (around 85 % of
deposition in the thoracic region, p = 0,0623, no signifi-
cant difference). These results confirm that there is a
minimal impact of the inhalation mode and the pos-
tural conditions when the deposition of aerosol is
mainly governed by diffusion. In contrast, disparate de-
position results were observed for the [0.25 μm–1 μm]
aerosols between the chimeric model and studies on
baboon (p < 0,0001, significant difference). This result
suggests that there is a high impact of the respiratory
mode and the postural conditions when the deposition
of aerosol is mainly governed by sedimentation.
To sum up, for sedimentation mechanism, the pos-
tural position (erect or supine) has a significant influ-
ence on the regional deposition whereas it is less
important for the impaction and diffusion processes
where the gravity does not play a major role [34–37].
We assume that the regional aerosol deposition differ-
ences observed between the proposed ex vivo model and
the in vivo experiments for the [0.25 μm–1 μm] aerosols
can be mainly attributed to the influence of postural
conditions. The limit of the ex vivo respiratory tract is
the supine position during the inhalation experiment
modifying the effects of gravity during the aerosolization
compared to in vivo data obtained in the erect position.
Thus, the chimeric model appears as quite reliable for
predicting regional aerosol deposition for all aerosol size
ranges, except for aerosol deposition governed by sedi-
mentation as an inhalation experiment in erect position
is needed. Technical solutions to perform the same ex-
periments in erect position are under active consider-
ation progress. The proposed ex vivo respiratory tract is
Fig. 4 a SPECT/CT imaging of the lung and delimitation of the central and peripheral regions of interest (red). b Percentage of deposition in the
central and peripheral regions obtained for each [d16–d84] size range: [0.15 μm–0.5 μm], [0.25 μm–1 μm] and [1 μm–9 μm]
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an important tool to address the three R’s approach for
aerosol deposition studies (Replacement: methods that
do not employ animals; Reduction: methods that result
in the use of fewer animals than existing methods;
Refinement: methods or techniques that reduce pain,
distress or discomfort to the animal), encouraging alter-
natives to in vivo animal testing.
Conclusion
This study presents original regional deposition data for
submicronic and micronic particles in an ex vivo respira-
tory tract and compares these to in vivo data. Results
clearly demonstrate a quite good agreement between the
regional aerosol deposition obtained for [1 μm–9 μm]
and [0.15 μm–0.5 μm] polydisperse aerosols compared
to in vivo inhalation experiments in baboons, healthy
human volunteers and the ex vivo model. However, a
bias induced by the use of the ex vivo respiratory tract
(with experiments currently performed in supine pos-
ition, see Fig. 1) was noticed for the aerosols with a de-
position mechanism governed by gravity (0.25 μm–1 μm
range) in comparison with in vivo inhalation experi-
ments performed in the erect position (0.25 μm–1 μm
range). In conclusion, this study shows that the ex vivo
respiratory tract proposed appears as quite reliable to as-
sess aerosol deposition for a wide range of polydisperse
aerosols (from sub-micron to micron sized particles), in-
halation mode (nasal and oro/nasal administration) and
postural positions (supine and erect positions). Thus, the
methodology developed is useful to better understand
the regional deposition of aerosols within the respiratory
tract raising interesting ethical and cost issues, mainly to
involve alternative methods as defined by the three R’s
approach.
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